title: Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder.
abstract: This study was designed to investigate the efficacy of the antidepressant fluvoxamine in the treatment of combat-related post-traumatic stress disorder (PTSD). Fifteen veterans with combat-related PTSD and no other psychiatric diagnosis except depression were recruited to participate in a 14-week open-label study of fluvoxamine. Patients underwent a 30-day washout period and were rated with the Clinician Administered PTSD Scale (CAPS), Mississippi Scale, Beck Depression Inventory (BDI), Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) at baseline, and every 2 weeks until week 14. Three patients stopped fluvoxamine prematurely due to side effects and 7 withdrew consent before completing the 14-week trial. Eight patients completed at least 8 weeks of treatment. The total daily dose of fluvoxamine ranged from 100 to 300 mg with a mean daily dose of 150 mg at week 14. Intent-to-treat analysis revealed a significant improvement in total CAPS scores, and in the intrusion and the avoidance/numbing subscales. The CAPS hyper-arousal scores did not change significantly. HAM-A score also improved significantly. No significant changes were seen on the Mississippi scale, HAM-D, or Beck Depression Inventory in the intent-to-treat analysis. In summary, our study shows that fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted.
authors.affiliation: Psychiatry Service, VA Medical Center, Albuquerque, New Mexico 87018, USA.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Escalona
authors.forename: Jose M
authors.initials: JM
authors.lastname: Canive
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Calais
authors.forename: Jonathan R T
authors.initials: JR
authors.lastname: Davidson
mesh_terms: D003863:Depression / Q000175:diagnosis; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000523:psychology*; D013997:Time Factors; D014728:Veterans / Q000523:psychology*
chemical_list: D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors